Are You Attending ASCO 2018?
Schedule A Meeting With Accelovance
The American Society for Clinical Oncology Annual Meeting is fast approaching, June 1-5 in Chicago. Whether you're still in the early planning phase or you have a candidate ready for clinical testing, we are here to help your organization achieve excellence in execution.
Accelovance is an award-winning, clinical development CRO focused on oncology and immunology programs across phase I-IV. Accelovance has conducted more than 150 oncology and hematology clinical trials across the globe, spanning a full range of tumor types. The team’s immuno-oncology experience includes:
- immune checkpoint modulators
- cellular immunotherapies
- oncolytic viruses
- peptide vaccines
- bispecific T-cell engagers
The HERO™ Initiative by Accelovance is a specialized early phase oncology program providing emerging and established biotech and pharmaceutical companies an accelerated means of advancing their early phase cancer compounds through clinical testing. With HERO™, clients benefit from automated technologies and systems, tailored to early phase oncology studies, to expedite trials while keeping costs down. Additionally, access to the best oncology sites gets you the patients you need, faster and easier than before.
Accelovance’s oncology experts work with you to customize your protocol and study design for an optimal outcome. Accelovance provides clients with the scale, expertise, and senior management commitment to maintain immediate and consistent engagement with your team at all times throughout the course of your program, to ensure the successful execution and delivery of your oncology studies.
Let us share with you our learnings and best practices for success, including ways to expedite timelines and reduce trial costs. Schedule a meeting to speak with our oncology experts by completing the form on this page.